Sbme studies have indicated that PGs can modulate the single nephron tubuloglomerular feedback (TGF) response. The aim of this study was to define the specific role of the vasoconstrictor PG, TX, by administration to rats of either vehicle (group 1; n = 20) or drugs that inhibit either cyclooxygenase (indomethacin lindol, 5 mg * kg-', group 2, n = 17), TX synthetase 485 [UK], 100 mg kg-', group 3, n = 19), or TX receptors 548 [SQJ, group 4, n = 14,953 [L, 50 mg. kg-', group 5, n = 8). Indo reduced excretion of the prostacyclin derivative 6-keto-PGF14, and TXB2 and lowered whole kidney GFR and renal plasma flow, whereas UK lowered excretion of TXB2 only and did not change basal renal hemodynamics. The TGF response (assessed from reduction in proximal tubule stop-flow pressure (Pf, mmHg) during increases in perfusion of the loop of Henle (LH) from 0 to 40 nl* min-') was unchanged after vehicle (9.8±0.5-10.9±1.0, NS) but blunted (P < 0.001) by 40-65% in rats of groups 2-5 (indo, 11.1±1.0-4.4±0.7; UK, 9.0±0.8-4.8±0.7; SQ, 10.3±0.6-4.8±0.6; L, 10.7±0.5-6.7±13). This blunting was due to lower values for Pdf at zero LH flow after indo, SQ, and L, and higher values of Pf at 40 nl. min'1 LH flow after indo and UK. The fall in single nephron GFR (SNGFR, nl min-1) with increasing LH perfusion was unchanged after vehicle (10.9±2.8-11.2±0.8) but was blunted (P < 0.05) by 45-55% in rats given indo (13.9±1.2-6.2±2.2) or UK (12.8±2.1-7.0±1.5). UK produced dose-dependent reductions in TXB2 excretion (IC50, 15 mg * kg-lJ and inhibition of the TGF response (IC5o: 30 mg-kg-'). After blockade of TX receptors by SQ, UK had no further affect on the TGF response. The fall in Pf at high LH flow was blunted (P < 0.05) by indo and UK, whereas the rise in Pf at zero LH flow was blunted by indo, SQ, and L. 
Introduction
The tubuloglomerular feedback (TGF)' response is an itnportant intrarenal process regulating GFR. The response is initiated by an increased delivery of sodium and chloride to the macula densa segment (1) . The resulting changes in GFR are due to changes in plasma flow rate and glomerular capillary hydrostatic pressure, and perhaps also to changes in the glomerular capillary filtration coefficient (2) . The mediators of these hemodynamic adjustments are not fully understood.
Thus, the TGF response is blunted, but nbt abolished, by the blockade of either angiotensin-converting enzyme with captopril or angiotensin II (All) receptors with saralasin (3). Likewise, the response is blunted, but not abolished, by blockade of cyclooxygenase with indomethacin (indo) or meclofenamate (4) (5) (6) . Simultaneous blockade of AII generation and PG production with captopril and meclofenamate abolishes TGF-induced changes in glomerular capillary hydrostatic pressure although some changes in single nephron GFR (SNGFR) persist (7l). The cyclooxygenase metabolite(s) that modulate the TGF response have not been elucidated.
TX is a cyclooxygenase metabolite that is produced by normal kidieys (8) or isolated glomeruli (9-1 1) and might be a vasoconstrictor agent regulating GFR. Indeed, activation of TGF in a whole-kidney model in which vasoconstriction was induced by intrarenal infusion of hyp@honic chloride-containing solutionis was accompanied by release ofthromboxane B2 (TXB2) (8) . The aim of the present study was to investigate the role of TX in a single-nephron model ofthe TGF response. We measured changes in SNGFR and proximal tubule stopflow pressure (Pf), which is an index of glomerular capillary hydrostatic pressure, during changes in tht rate ofperfusion of the loop of Henle (LH). Louis, MO) were dissolved in 0.15 M NaCl and the solution infused at 0.5 ml* 100 g body wt (bw)-h-h', after a priming dose of 0.5 ml to maintain a euvolemic state. Experiments followed a standard protocol. After surgery, there was a 30-min equilibration period followed by a control period of 90 min (period 1) during which clearance and micropuncture measurements were made. Thereafter, test solutions or vehicle were infused over a 5-min period, followed by a 15-min period for equilibration. There were six experimental groups. Group I received vehicle, group 2 received indo (5 mg* kg-'), group 3 received UK (100 mg-kg-'), group 4 received SQ (8 mg-kg-'), and group 5 received L (50 mg kg-'). 20 min after administration of vehicle or drugs, there was a 90-min experimental period (period 2) during which similar measurements and collections were made as in period 1. Urine was collected during periods I and 2, and a 0.6-ml blood sample was drawn at the end of each. The different treatment groups are summarized in Table I . The preliminary results showed that the effects of SQ (group 4) and L on the TGF response were similar, and therefore a complete analysis of the response to TX receptor blockade was undertaken in the former group only.
Group 6 rats received SQ (8 mg-kg-') during period 2. 15 min thereafter, clearance and micropuncture measurements were made, after which a second dose of SQ (8 mg. kg-') was given with UK (100 mg* kg-'). After another 15 min, clearance and micropuncture measurements were repeated. Thus, in this group the effects of the'bockade of TX synthesis with UK could be studied in animals whose TX receptors had been blocked by SQ.
The dose-response relationships for the effect of UK on excretion of TXB2 and on the TGF response were studied in rats receiving the following doses (mg* kg-') of UK: 1, 10, 50, 100, and' 500. Clearance and micropuncture studies were performed as described above. One rat given the highest dose showed signs oftoxicity (reduced BP) and its data were discarded.
Drugs. Indo inhibits cyclooxygenase and reduces the production of all PGs including PGI2 and TX (4, 6, 7) . Indo (2.5 mg -ml-', Sigma Chemical Co.) was dissolved in 1 M Na2CO3 solution and given to group 2 rats to assess the effects of nonselective inhibition of production ofboth vasodilator and vasoconstrictor PGs on the TGF response. UK (Pfizer-Central Research, Groton, CT) is a selective inhibitor of TX synthesis (12) (13) (14) 15 ) with the formula: 3-(l1H-imidazol-l-ylmethyl)-2-methyl-I H-indole-I -propanoic acid. It was dissolved in 1 N NaOH at pH 12.5 and titrated with 1 N HCI to pH 8.5 to a concentration of 100 mg * ml-'. It was given to group 3 rats to assess the effects of Assayfor TXB2 and 6-keto-PGFja (6kPGFIJ
The purification and assay of the PGI2 derivative 6kPGFIa (Seragen Inc., Boston, MA) and TX132 in urine was developed from a previous method (8) . Samples (0.5 ml) of urine were spiked with -1,000 cpm of [3H] TXB2 (New England Nuclear, Boston MA) as a tracer to assess the individual recovery of each sample assayed and diluted with 0.5 ml of deionized water to facilitate organic extraction. The pH was adjusted from 3.0 to 3.5 with 1.0 N HC1 and samples were extracted with 8-ml ethyl acetate. The organic phase was dried under nitrogen and dissolved in 50 ,ul of acetone. Each 50!-Ml sample was placed as a single spot on a 20 X 20-cm silica gel C-plate (Fisher Scientific Co., Pittsburgh, PA) at nine spots per plate. Standard TXB2 and 6kPGFI were spotted individually on one plate. Plates were developed in CHC13/ MEOH/HOAC (90:10:5). The standards were visualized with anisealdehyde reagent spray; TXB2 appeared at reference point 0.65 and 6kPGFI at reference point 0.70. Corresponding sample areas were scraped, extracted with 8 ml of methyl formate, centrifuged at 2,600 rpm, dried under nitrogen, and dissolved in 500 ,ul of phosphate buffer (pH 7.4). A 50-MLl aliquot was used for calculation ofindividual sample recoveries, and the remainder was used for radioimmunoassay.
Radioimmunoassay was carried out in a 4°C ice bath in 12 X 75-cm disposable glass tubes to which were added 200 Ml of phosphate buffer (pH 7.4) and 100 Md of either standard or sample. Antisera (100 Al, Seragen, Inc.) was added and the samples vortexed. After 15 min, 100 ,ul of -100 cpm .Ml-' of [3H] antigen (New England Nuclear) was added to each tube and vortexed. The tubes were covered with parafilm'and incubated at 4°C for 18 h. Samples were precipitated with 500 Ml dextran-coated charcoal for 15 min and centrifuged at 2,650 rpm for 10 min. We recovered 500 Ml of each sample immediately and placed it in a scintillation vial for counting in a liquid scintillation counter (model LS7000; Beckman Instruments, Inc., Fullerton, CA).
The assay had an interassay coefficient of variation (n 31) for TXB2 of 7.6% and for 6kPGFI. of 8.3%. The sensitivity was 5-10 pg. ml-'. The accuracy was assessed each week by addition of 1,000 pg of TXB2 and 6kPGF1a to 1 ml of rat urine. The results were +975±22 pg ml-' (n = 23) for 6KPGFI. and +1,001±26 pg ml-' (n = 26) for Pf was measured at zero loop perfusion at the beginning and end of each series. If these values differed by > 1 mmHg, the data were discarded. It was technically harder to undertake recovery measurements of SNGFR. In 32 preliminary studies, SNGFR was measured first at zero loop perfusion; the SNGFRs recorded in this group at 0 and 40 nl min-' of LH perfusion were 35±2 and 21±2 nl min-', respectively. In 13 rats, SNGFR was measured first at 40 nl min-' loop perfusion; the SNGFRs recorded in this group at 0 and 40 nl * min' of LH perfusion were similar at 37±2 and 20±2 nl * min-'. Therefore, the order in which measurements were made did not appear to influence the response. Nevertheless, the order of studies was randomized between rats.
Values are reported as mean±1 SEM. Differences between groups were assessed by analysis of variance (ANOVA) with a Student's t test to assess posthoc differences. Values were taken as statistically significant at P < 0.05.
Results
The effect of each drug treatment on mean blood pressure (MBP) and whole kidney function is shown in Table I . The body weights were not different between the groups. The data obtained in the basal state (period 1) did not differ between groups. The results of an ANOVA indicated that, compared with vehicle, indo reduced urine flow, whereas UK increased urine flow and chloride excretion.
The effects of drugs on renal excretion of TXB2 and 6kPGFia are shown in Fig. 1 . Urine volumes were insufficient for measuring PG or TXB2 excretion in 10% of the rats. During period 1, there were no differences in excretion between the three groups. Administration of vehicle (group 1) did not change excretion of TXB2 or 6kPGFIa (data not shown). Compared with vehicle, treatment with indo (group 2) or UK (group 3) decreased the excretion of TXB2 consistently, whereas the excretion of 6kPGFI,, was decreased only by indo.
Group mean changes in P5f during increases in the rate of However, the results of ANOVA and posthoc t tests demonstrate that after treatment (period 2), the P5f at zero perfusion of the LH was lower in animals pretreated with indo (P < 0.005), SQ (P < 0.01), or L (P < 0.05) compared with those receiving vehicle, whereas the Pfduring perfusion ofthe LH at 40 nl* min' was greater (P < 0.05) in animals that had received indo or UK. During period 1, there were no differences between the groups for the changes in Pfduring increase in LH perfusion from 0 to 40 nl -min'. During period 2, administration of indo, UK, SQ, and L all reduced (P < 0.005) the TGF response compared with group 1 rats that had received vehicle. During period 1, the values of SNGFR recorded at perfusion ofthe LH at 0 and 40 nl -min' and the differences in SNGFR between these two perfusion rates did not differ between groups (Table II) . After administration ofvehicle (group 1), the SNGFR response to changes in LH perfusion were comparable. In contrast, after administration of indo (group 2) or UK (group 3) there were significant reductions in SNGFR responses to increasing LH perfusion. After indo, the overall blunting ofthe TGF response assessed from changes in P51 was comparable with that assessed from changes in SNGFR and averaged -60 and -58%, respectively. After UK, the blunting was also comparable, -47 and -45%, respectively. However made did not affect the results obtained. Thus, after vehicle administration, eight rats were studied first at zero loop perfusion; their values for SNGFR at 0 and 40 nl* min' of loop perfusion were 29±4 and 19±3 nl -min-', compared with values of 30±4 and 17±4 nl* min-' in five rats studied first at 40 nl* min-'. After indo, nine rats were studied first at zero loop perfusion; their values for SNGFR at 0 and 40 were 27±3 and 20±4 compared with values of 24±5 and 21±3 in three rats studied first at 40 nl* min-'. After UK, seven rats were studied first at zero loop perfusion; their values for SNGFR at 0 and 40 nl * min' were 22±3 and 16±2 nl * min-' compared with values of 25±1 and 18±3 in six rats studied first at 40 nlo min-'. The dose-response relationship for UK on renal TXB2 excretion is compared with that on the TGF response in Fig. 3 . The fractional changes in TXB2 excretion and TGF during period 2 (after administration of the drug) are compared with the control period 1. TXB2 excretion was maximally suppressed by 100 mg kg-'; the IC50 was 15 mg-kg-'. The TGF response was maximally suppressed by 100 mg* kg-'; the IC50 was 30 mg-kg-'.
The mean values of Pf at incremental rates of LH perfusion are shown in Fig. 4 . During period 1, there was a sigmoidal reduction in Psf with increasing LH perfusion in each group. The rate of LH perfusion associated with a 50% reduction in Psf averaged 15-20 nlo min-'. After administration of vehicle, there were no consistent changes. Indo and SQ flattened the response by reducing Psf at low and high rates of LH perfusion, whereas the effects of UK were significant only at the high rates of LH perfusion.
The Psf at graded rates of LH perfusion was studied in seven rats before administration ofdrugs, after administration of SQ, and after UK plus SQ (Fig. 5) . SQ reduced Pf at zero perfusion of the LH and increased it at 40 nlo min-' of LH perfusion, as in the previous series (Fig. 4) . After administration of SQ, UK had no further effect on Psf at any rate of LH perfusion, although the value at zero LH perfusion was now not quite significantly lower than during period 1 lites) over the time at which it blunted the TGF response. In contrast, UK is a competitive inhibitor of TX synthetase (15, 16) . It produced dose-dependent inhibition of the TGF response and excretion of TXB2 without affecting 6kPGFI.
This confirms previous studies using GCMS (14) , thin-layer chromatography (13) seen at 40 nl* min-of LH perfusion, although both drugs blunted the overall TGF-induced changes in SNGFR by 45-55%. Indo, SQ, and L reduced Psf significantly during perfusion of the LH at zero flow, implying that they blunted the vasodilator arm of the TGF response. Previously, indo has been shown to blunt the overall TGF response assessed from changes in early proximal flow rate without changing significantly the early proximal flow rate at zero LH perfusion (4) . A blunting of the vasodilator and vasoconstrictor arms of the TGF-induced changes in P5f might relate to diminished production by indo of both vasodilator PGs and TXA2. However, it is hard to reconcile this conclusion with results of previous studies (4), which showed the time course of inhibition of the TGF response by indo did not correspond with that for inhibition of PG excretion. Moreover, this would not explain why administration of SQ and L also reduced Pf during perfusion of the LH at zero flow. The values for Pf and SNGFR at zero (7) observed that the combined administration ofa cyclooxygenase inhibitor (meclofenamate) and an angiotensin-converting enzyme inhibitor (MK42 1) abolished TGF-induced changes in P,&, while only blunting changes in SNGFR. They proposed that the changes in SNGFR at constant glomerular capillary pressure reflected parallel alterations in pre-and postglomerular vascular resistances. We observed quite comparable degrees of inhibition of the overall TGF response assessed from measurements of SNGFR or Pf in rats treated with either a cyclooxygenase inhibitor, a TX synthetase inhibitor, or TX receptor antagonists. This is consistent with the effects of TX or stable mimetics in increasing vascular resistance, especially at preglomerular sites, when added to the perfusate of isolated kidneys and in constricting isolated glomeruli (23) . These data indicate that TXA2 modulates TGF-induced changes in SNGFR, at least in part by regulating the glomerular pressure.
